IBDEI079 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,2891,0)
 ;;=Z21.^^7^84^.1
 ;;^UTILITY(U,$J,358.3,2891,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2891,1,3,0)
 ;;=3^HIV+ Status (Asymptomatic)
 ;;^UTILITY(U,$J,358.3,2891,1,4,0)
 ;;=4^Z21.
 ;;^UTILITY(U,$J,358.3,2891,2)
 ;;=^5062777
 ;;^UTILITY(U,$J,358.3,2892,0)
 ;;=B20.^^7^84^.5
 ;;^UTILITY(U,$J,358.3,2892,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2892,1,3,0)
 ;;=3^HIV+ (Symptomatic)/AIDS
 ;;^UTILITY(U,$J,358.3,2892,1,4,0)
 ;;=4^B20.
 ;;^UTILITY(U,$J,358.3,2892,2)
 ;;=^5000555
 ;;^UTILITY(U,$J,358.3,2893,0)
 ;;=Z23.^^7^84^28
 ;;^UTILITY(U,$J,358.3,2893,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2893,1,3,0)
 ;;=3^Encounter for Immunization
 ;;^UTILITY(U,$J,358.3,2893,1,4,0)
 ;;=4^Z23.
 ;;^UTILITY(U,$J,358.3,2893,2)
 ;;=^5062795
 ;;^UTILITY(U,$J,358.3,2894,0)
 ;;=Z20.828^^7^84^17
 ;;^UTILITY(U,$J,358.3,2894,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2894,1,3,0)
 ;;=3^Contact/Exposure to Viral Diseases
 ;;^UTILITY(U,$J,358.3,2894,1,4,0)
 ;;=4^Z20.828
 ;;^UTILITY(U,$J,358.3,2894,2)
 ;;=^5062774
 ;;^UTILITY(U,$J,358.3,2895,0)
 ;;=Z77.21^^7^84^16
 ;;^UTILITY(U,$J,358.3,2895,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2895,1,3,0)
 ;;=3^Contact/Exposure to Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,2895,1,4,0)
 ;;=4^Z77.21
 ;;^UTILITY(U,$J,358.3,2895,2)
 ;;=^5063323
 ;;^UTILITY(U,$J,358.3,2896,0)
 ;;=Z72.51^^7^84^56
 ;;^UTILITY(U,$J,358.3,2896,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2896,1,3,0)
 ;;=3^High Risk Sexual Behaviors
 ;;^UTILITY(U,$J,358.3,2896,1,4,0)
 ;;=4^Z72.51
 ;;^UTILITY(U,$J,358.3,2896,2)
 ;;=^5063258
 ;;^UTILITY(U,$J,358.3,2897,0)
 ;;=Z79.899^^7^84^66
 ;;^UTILITY(U,$J,358.3,2897,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2897,1,3,0)
 ;;=3^Long Term Use of Medications
 ;;^UTILITY(U,$J,358.3,2897,1,4,0)
 ;;=4^Z79.899
 ;;^UTILITY(U,$J,358.3,2897,2)
 ;;=^5063343
 ;;^UTILITY(U,$J,358.3,2898,0)
 ;;=A06.9^^7^84^1
 ;;^UTILITY(U,$J,358.3,2898,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2898,1,3,0)
 ;;=3^Amebiasis
 ;;^UTILITY(U,$J,358.3,2898,1,4,0)
 ;;=4^A06.9
 ;;^UTILITY(U,$J,358.3,2898,2)
 ;;=^5000048
 ;;^UTILITY(U,$J,358.3,2899,0)
 ;;=K60.2^^7^84^2
 ;;^UTILITY(U,$J,358.3,2899,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2899,1,3,0)
 ;;=3^Anal Fissure
 ;;^UTILITY(U,$J,358.3,2899,1,4,0)
 ;;=4^K60.2
 ;;^UTILITY(U,$J,358.3,2899,2)
 ;;=^5008747
 ;;^UTILITY(U,$J,358.3,2900,0)
 ;;=K60.3^^7^84^3
 ;;^UTILITY(U,$J,358.3,2900,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2900,1,3,0)
 ;;=3^Anal Fistula
 ;;^UTILITY(U,$J,358.3,2900,1,4,0)
 ;;=4^K60.3
 ;;^UTILITY(U,$J,358.3,2900,2)
 ;;=^6684
 ;;^UTILITY(U,$J,358.3,2901,0)
 ;;=K62.82^^7^84^4
 ;;^UTILITY(U,$J,358.3,2901,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2901,1,3,0)
 ;;=3^Anal Intraepithelial Neoplasia/AIN
 ;;^UTILITY(U,$J,358.3,2901,1,4,0)
 ;;=4^K62.82
 ;;^UTILITY(U,$J,358.3,2901,2)
 ;;=^5008758
 ;;^UTILITY(U,$J,358.3,2902,0)
 ;;=D64.9^^7^84^5
 ;;^UTILITY(U,$J,358.3,2902,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2902,1,3,0)
 ;;=3^Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,2902,1,4,0)
 ;;=4^D64.9
 ;;^UTILITY(U,$J,358.3,2902,2)
 ;;=^5002351
 ;;^UTILITY(U,$J,358.3,2903,0)
 ;;=R64.^^7^84^6
 ;;^UTILITY(U,$J,358.3,2903,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2903,1,3,0)
 ;;=3^Cachexia
 ;;^UTILITY(U,$J,358.3,2903,1,4,0)
 ;;=4^R64.
 ;;^UTILITY(U,$J,358.3,2903,2)
 ;;=^17920
 ;;^UTILITY(U,$J,358.3,2904,0)
 ;;=B37.81^^7^84^7
 ;;^UTILITY(U,$J,358.3,2904,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2904,1,3,0)
 ;;=3^Candidiasis,Esophageal
 ;;^UTILITY(U,$J,358.3,2904,1,4,0)
 ;;=4^B37.81
 ;;^UTILITY(U,$J,358.3,2904,2)
 ;;=^5000620
 ;;
 ;;$END ROU IBDEI079
